Tag: Waldenström Macroglobulinemia

1. Bruton’s tyrosine kinase inhibitor pirtobrutinib showed efficacy in the treatment of relapsed or refractory B-cell malignancies such as chronic ...

1. Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, produced a response in 90.5% of patients with Waldenström’s macroglobulinemia. 2. Patient ...

Originally published by Harvard Health. What Is It? Waldenström macroglobulinemia (WM) is a rare, slow-growing cancer. It is a form of ...